Αποτελέσματα Αναζήτησης
19 Ιουν 2023 · All participants received 18 weeks of chemotherapy with paclitaxel 80 mg/m 2 IV once weekly and non-pegylated liposomal doxorubicin 20 mg/m 2 IV once weekly. Patients with TNBC received simultaneous bevacizumab 15 mg/kg IV once every 3 weeks.
15 Φεβ 2023 · Triple-negative breast cancer (TNBC) accounts for 15–20% of all breast cancers and is characterized by an aggressive nature and a high rate of recurrence despite neoadjuvant and adjuvant chemotherapy.
14 Αυγ 2024 · The study aimed to assess the effectiveness and safety of dose-dense AC compared to every 3-week AC in patients with early-stage TNBC undergoing neoadjuvant chemotherapy plus pembrolizumab.
2 Φεβ 2022 · The results suggested that 4 cycles of AC followed by weekly paclitaxel (AC*4-wP*12) may be the preferred choice for adjuvant chemotherapy of TNBC patients. Capecitabine regimens As an oral prodrug of fluorouracil, capecitabine has shown high efficacy in the treatment of gastric cancer 23 , but its effectiveness in breast cancer remains ...
9 Νοε 2021 · In unselected patients with TNBC, the addition of anti-PD-1/PD-L1 antibodies to neoadjuvant chemotherapy increased the pCR rate by 2.8–17% 175,176,177,184. Whether the heterogeneity of...
29 Μαΐ 2020 · I-SPY 2 trial studied the neoadjuvant PARPi veliparib and carboplatin followed by AC as compared with standard neoadjuvant chemotherapy (paclitaxel followed by AC) . The estimated pCR rate in TNBC was 51% in the veliparib-carboplatin group vs. 26% in the control group.
29 Οκτ 2019 · NACT is associated with increased rate of pathologic complete response (pCR), which has been associated with reduced risk of death and recurrence in all subtypes, including TNBC. 3 Residual cancer burden (RCB) after NACT has also been shown to predict disease recurrence and survival across all subtypes. 8 Additionally, neoadjuvant treatment ...
